Wed.Oct 23, 2024

article thumbnail

Vaccination Key to Preventing COVID-19 Hospitalizations Among Children

Drug Topics

A study found that children aged 6 months or younger who are not eligible for vaccination were at the highest risk for hospitalization due to SARS-CoV-2.

Hospitals 220
article thumbnail

Clinicians, Pharmacists Should Work to Ensure Safety Compounded GLP-1 Medications

Pharmacy Times

Pharmacists can educate patients about how to recognize unsafe online sources of medications and ensure patients are properly educate on how to administer their medications.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Exploring Alternative Pain Management Strategies for Headaches and Migraines | AMCP Nexus 2024

Drug Topics

New research presented at AMCP Nexus 2024 highlighted the effectiveness and cost-effectiveness of various migraine treatments, including onabotulinumtoxinA and fremanezumab, as well as the importance of migraine education programs for improving patient outcomes.

189
189
article thumbnail

What to Know About E Coli Outbreak Linked to McDonald’s Quarter Pounders

Pharmacy Times

Pharmacists will likely be the first contact for many affected patients, and they should be able to provide evidence-based advice on how to manage their infection.

153
153
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

STAT+: Frustrated with Change Healthcare breach, senators propose removing limits on HIPAA fines

STAT

Linda Barbour thought she was more interested in the Change Healthcare cyberattack than most. Having worked as a medical director for several large health insurance companies and having suffered through the Change fiasco herself as a rehab doctor with a private practice in Kansas City, she figured that if her data had been exposed in that February breach, she would have been notified by now.

HIPAA 130
article thumbnail

Data From 5 Studies Show Benefit of Cell-Based Influenza Vaccines

Pharmacy Times

Benefits include reducing serious health consequences, such as hospitalization and death, as well as the economic burden on health systems due to influenza infection.

Vaccines 139

More Trending

article thumbnail

Healthy Sleep Patterns Reduced Risk of Digestive Disease

Drug Topics

Researchers addressed the association between sleep patterns and digestive diseases, as well as patients’ genetic likeliness of developing future digestive complications.

112
112
article thumbnail

STAT+: Q&A: Mark Cuban explains his beef with traditional PBMs — and why he thinks they’re destined to fail

STAT

Mark Cuban is a man on a mission — to disrupt the pharmaceutical industry. Specifically, Cuban, the billionaire best known for his past role on the TV show “Shark Tank” and his minority stake in the Dallas Mavericks, is seeking to disrupt the middlemen known as pharmacy benefit managers. He’s done that in part with the Mark Cuban Cost Plus Drug Company, which he launched in 2021 and which he says is a cheaper alternative to traditional PBMs.

128
128
article thumbnail

Transforming Oncology Care: Insights into NCODA’s PQI Initiatives

Pharmacy Times

Ginger Blackmon, PharmD, will discuss enhancing patient cancer care through implementation of medically integrated oncology team and NCODA’s PQI resources.

131
131
article thumbnail

STAT+: U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value

STAT

LONDON — For the second time in a matter of months, the U.K.’s cost-effectiveness watchdog has said the limited benefits of a newly approved Alzheimer’s drug do not justify its costs, threatening the possibility of the medicine reaching patients. The National Institute for Health and Care Excellence said in draft guidance released Wednesday that the drug, Eli Lilly’s donanemab, “cannot currently be considered good value for the taxpayer,” given the

127
127
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

FDA Approves Abrysvo to Treat Adults 18 to 59 Years of Age at Increased Risk for RSV

Pharmacy Times

The approval marks Abrysvo as the first and only RSV vaccine designated for adults younger than 50 that are at increased risk for LRTD.

Vaccines 139
article thumbnail

More state Medicaid programs consider covering GLP-1 drugs

STAT

Most state Medicaid programs don’t cover the new class of weight loss drugs for obesity, but that could soon change. Half of those that don’t are considering adding coverage, per a new KFF report.  While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, it’s much less common for them to cover the drugs for obesity.

127
127
article thumbnail

In boon for Pfizer and Merck, CDC panel backs expanded use of pneumococcal vaccines

Fierce Pharma

With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP), pneumococcal conjugate vaccines (PCV) from Pfizer and | The CDC's immunization committee voted to expand the recommendation for pneumococcal conjugate vaccines, including both Pfizer’s Prevnar 20 and Merck’s newer Capvaxive.

Vaccines 125
article thumbnail

Opinion: How to make sure opioid settlement money isn’t wasted

STAT

The opioid and overdose crisis is a national tragedy, claiming more than 1 million lives since 1999. In the past three years, more than $55 billion has flowed into state, county, and city coffers from opioid manufacturers, distributors, and chain pharmacies as a result of their collective role in instigating and perpetuating this public health crisis.

123
123
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Novo joins Lilly in asking FDA for ban on GLP-1 compounding

pharmaphorum

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely by these manufacturers.

article thumbnail

STAT+: What’s on the docket for Congress post-election: Chinese biotech, Medicare payments, ACA subsidies

STAT

WASHINGTON — When Congress returns on Nov. 12 after the elections, lawmakers will have just over a month to fund the government.  That deadline pressure creates an opportunity to potentially enact health care legislation. Regardless of what happens this year, next year will be huge for health care policy, in part because lawmakers need to address major expiring policies.

122
122
article thumbnail

HLTH24: Employers still in an 'experimental' mode around GLP-1s

Fierce Healthcare

LAS VEGAS — Demand for GLP-1s has not slowed, and employers still have not cracked the code on the perfect solution for medications that represent a growing portion of spend. | LAS VEGAS — Demand for GLP-1s has not slowed, and employers still have not cracked the code on the perfect solution for medications that represent a growing portion of spend.

109
109
article thumbnail

Scientists used infrared light to create artificial vision in patients with vision loss

STAT

Science Corporation published preliminary data from a late stage, multi-center clinical trial of a retinal implant that showed promising results Tuesday. Using this prosthetic, scientists partially restored vision to people whose central visual field has holes or blurry spots. Trial participants could read text and recognize playing cards when using the implant, even though they were legally blind.

129
129
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Rise of almost untreatable superbug linked to a common antibiotic

The Guardian - Pharmaceutical Industry

‘Surprising’ finding by Australian-led study is first recorded instance of one antibiotic causing resistance to another in a different class Follow our Australia news live blog for latest updates Get our breaking news email , free app or daily news podcast The rise of an almost untreatable superbug has been linked to a common antibiotic, an Australian-led study has found.

109
109
article thumbnail

Wojcicki projects confidence amid 23andMe stumbles

STAT

This story first appeared in The Readout newsletter.  Sign up for The Readout  and receive STAT’s award-winning biotech news delivered straight to your inbox.  Good morning. It’s been a while since I shared some local news: Chicago has yet again proved itself not only to be the best, but also the rattiest city in the U.S.

107
107
article thumbnail

Sanford Health, Marshfield Clinic Health System officially ink merger agreement

Fierce Healthcare

Sanford Health and Marshfield Clinic Health System have signed a merger agreement, the health systems announced on Wednesday, after first revealing their intent to combine in July. | Sanford Health and Marshfield Clinic Health System have signed a merger agreement, the health systems announced on Wednesday, after first revealing their intent to combine in July.

106
106
article thumbnail

STAT+: Morning Rounds: Study on racial health disparities called into question

STAT

Does anyone here listen to Who Weekly? They sort celebrities into “Whos” (the not-as-famous) and “Thems” (the universally-well-known). So, like: RFK is a Them, while Casey and Calley Means are Whos. The study below on sense of smell and breathing made me think: What’s the Who-to-Them ranking of the five senses? First I thought smell was the Whoiest, but my editor wisely suggested touch as the sense people most often forget.

105
105
article thumbnail

Novo Nordisk asks FDA to prevent compounders from making copycat versions of GLP-1 star semaglutide

Fierce Pharma

The war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants Novo Nordisk and Eli Lilly, who want to protect their right to sell their patent | Novo Nordisk has asked the FDA to prevent compounders from manufacturing copycat versions of its juggernaut diabetes and obesity treatments Ozempic and Wegovy, claiming the drugs are too complex to safely replicate.

article thumbnail

STAT+: Pharmalittle: We’re reading about Novo targeting compounded obesity drugs, an Amgen ‘at risk’ launch, and more

STAT

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.

article thumbnail

Lawmakers seek answers on Pfizer, Lilly telehealth moves

pharmaphorum

US lawmakers fear Pfizer and Lilly's recent forays into direct-to-consumer distribution of medicines via telehealth could violate anti-kickback laws.

109
109
article thumbnail

The Association Between Cardiac Surgery and Gastrointestinal Complications

Drug Topics

In a comprehensive literature review, researchers addressed the impact cardiac surgery has on gastrointestinal outcomes.

98
article thumbnail

Real-World Evidence Presented at IDWeek Demonstrates Efficacy of CAB LA When Used for HIV PrEP

Pharmacy Times

Cabotegravir long-acting when used for HIV pre-exposure prophylaxis (PrEP) showed adherence, effectiveness, and improvements in quality of life by those who received the injection.

127
127
article thumbnail

Pfizer gets a leg up in RSV as FDA clears jab for all adults

pharmaphorum

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference in the battle for market share.The US regulator has cleared Abrysvo for use in adults aged 18 to 59 at risk of RSV-related disease, extending its earlier label which covered the 60 and over age bracket.

FDA 97
article thumbnail

Amgen pledges to launch Eylea biosim after legal win—but Regeneron stresses the fight's not over yet

Fierce Pharma

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. | Amgen is preparing to launch its Eylea biosimilar, Pavblu, after another victory over Regeneron in court. That said, Regeneron is appealing the decision and stressed that it continues to believe Amgen's copycat infringes multiple Eylea patents.

106
106
article thumbnail

FDA To Reevaluate Removal of Tirzepatide From Drug Shortage List

Pharmacy Times

The agency does not intend to take action against the plaintiffs for the violation of the Federal Food, Drug, and Cosmetic Act, including the compounding of tirzepatide.

article thumbnail

Blue Cross plan accused of fraud in 'ghost network' class-action lawsuit

Fierce Healthcare

Anthem Blue Cross Blue Shield of New York’s directory of doctors is thoroughly inaccurate and forces patients to seek costly out-of-network care and delay care, a class-action lawsuit alleges. | Anthem Blue Cross Blue Shield of New York is making it hard for members to receive care from mental health professionals due to poorly run provider directories, or ghost networks, a lawsuit claims.

113
113
article thumbnail

FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV

Drug Topics

Abrysvo is the only RSV vaccine approved for use in this age group.

Vaccines 123
article thumbnail

Roche CEO says Novo's Catalent buyout 'could be a problem' for smaller drugmakers

Fierce Pharma

While Novo Holdings and Catalent continue to voice confidence that their planned $16.5 billion merger will go through before the year is out, the deal has received near-constant criticism over the | While Novo Holdings and Catalent continue to voice confidence that their planned $16.5 billion merger will go through before the year is out, the deal has received near-constant criticism over the past several weeks.

95